GlobeNewsWire·Jun 23, 2026
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney InjuryEnables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy
SeaStar Medical Holding Corporation(ICU)Earnings, Financials & Key Ratios
ICU•NASDAQ
$5.07
Price updated Jul 7, 2026
AboutSeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.Show more
- Revenue$1M+814.1%
- EBITDA-$12M+50.5%
- Net Income-$12M+51.1%
- EPS (Diluted)-5.86+91.2%
- Gross Margin95.7%-4.3%
- EBITDA Margin-986.63%+94.6%
- Operating Margin-986.63%+92.5%
- Net Margin-984.6%+94.6%
- ROE-295.15%
ICU Price & Volume
SeaStar Medical Holding Corporation (ICU) stock price & volume — 10-year historical chart
Loading chart...
High Gross Margins Mask Persistent Operational Losses
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- SeaStar Medical is currently navigating a critical transition from research-stage development to commercial scaling, evidenced by a 68.9% year-over-year revenue growth in 2026Q1.
- While the company maintains a robust 90.7% gross margin, the business model remains heavily dependent on external equity financing to offset recurring quarterly operating losses of $3.6M.
- Investors should monitor the progress of the NEUTRALIZE-AKI clinical trial, as the company's long-term viability hinges on successful regulatory milestones to mitigate its $155.2M accumulated deficit.
Verdict Logic
while the company shows early revenue growth, the $9.3M cash balance against persistent quarterly operating losses of $3.6M suggests significant execution risk and potential for further shareholder dilution.
ICU Growth Metrics
SeaStar Medical Holding Corporation (ICU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM235.51%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM25.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM88.17%
Return on Capital
10 Years-324.29%
5 Years-295.76%
3 Years-295.76%
Last Year-295.76%
ICU Recent Earnings
SeaStar Medical Holding Corporation (ICU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (57%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.90-23.3%
$0.73
Rev
$495,000+13.1%
$437,500
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.80+17.5%
$0.97
Rev
$420,000+88.8%
$222,500
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.30+13.3%
$1.50
Rev
$183,000-26.8%
$250,000
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.18+58.1%
$0.43
Rev
$338,000+38.0%
$245,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.90vs $0.73-23.3% | $495,000vs $437,500+13.1% |
| Q2 2026 | Mar 25, 2026 | $0.80vs $0.97+17.5% | $420,000vs $222,500+88.8% |
| Q4 2025 | Nov 13, 2025 | $1.30vs $1.50+13.3% | $183,000vs $250,000-26.8% |
| Q3 2025 | Aug 13, 2025 | $0.18vs $0.43+58.1% | $338,000vs $245,000+38.0% |
Based on last 12 quarters of dataView full earnings history →
Latest ICU News
Recent stock market news and headlines for SeaStar Medical Holding Corporation (ICU)
GlobeNewsWire·Jun 22, 2026
SeaStar Medical to Present at Upcoming Investor Summit ConferenceDENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time.
Peers Comparison
Key metrics vs top competitors for SeaStar Medical Holding Corporation (ICU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.07 | $198.66M | -0.87 | 814.07% | -984.6% | -295.15% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $1.36 | $364.83M | -65.38 | 47.46% | -8.83% | -62.72% | — | |
| $31.49 | $3.85B | 18.74 | 19.78% | 37.08% | 23.65% | — | |
| $43.89 | $550.42M | 30.06 | 83.06% | 86.97% | 30.21% | — |
Compare ICU vs Peers
SeaStar Medical Holding Corporation (ICU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ICU SEC Filings & Documents
SeaStar Medical Holding Corporation (ICU) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 25, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when ICU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ICU Frequently Asked Questions
SeaStar Medical Holding Corporation (ICU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is SeaStar Medical Holding Corporation's revenue?
SeaStar Medical Holding Corporation (ICU) reported $1.4M in revenue for fiscal year 2025.
How fast is SeaStar Medical Holding Corporation growing?
SeaStar Medical Holding Corporation (ICU) grew revenue by 814.1% over the past year. This is strong growth.
Is ICU profitable?
SeaStar Medical Holding Corporation (ICU) reported a net loss of $11.9M for fiscal year 2025.
Dividend & Returns
What is ICU's return on equity?
SeaStar Medical Holding Corporation (ICU) has a return on equity (ROE) of -295.2%. Negative ROE indicates the company is unprofitable.
What is SeaStar Medical Holding Corporation's free cash flow?
SeaStar Medical Holding Corporation (ICU) had negative free cash flow of $13.7M in fiscal year 2025, likely due to heavy capital investments.